EA201070271A1 - Пептиды для получения вакцины - Google Patents

Пептиды для получения вакцины

Info

Publication number
EA201070271A1
EA201070271A1 EA201070271A EA201070271A EA201070271A1 EA 201070271 A1 EA201070271 A1 EA 201070271A1 EA 201070271 A EA201070271 A EA 201070271A EA 201070271 A EA201070271 A EA 201070271A EA 201070271 A1 EA201070271 A1 EA 201070271A1
Authority
EA
Eurasian Patent Office
Prior art keywords
vaccine
peptides
receiving
prevention
treatment
Prior art date
Application number
EA201070271A
Other languages
English (en)
Other versions
EA023303B1 (ru
Inventor
Родерик Питер Хэфнер
Пол Лэйдлер
Марк Лярш
Original Assignee
Сиркейшиа Лимитед
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40134075&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EA201070271(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GB0715949A external-priority patent/GB0715949D0/en
Priority claimed from GB0716224A external-priority patent/GB0716224D0/en
Priority claimed from GB0723337A external-priority patent/GB0723337D0/en
Application filed by Сиркейшиа Лимитед filed Critical Сиркейшиа Лимитед
Publication of EA201070271A1 publication Critical patent/EA201070271A1/ru
Publication of EA023303B1 publication Critical patent/EA023303B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0003—Invertebrate antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/35—Allergens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/35—Allergens
    • A61K39/36—Allergens from pollen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/14—Ectoparasiticides, e.g. scabicides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/415—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from plants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/43504—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
    • C07K14/43513—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from arachnidae
    • C07K14/43531—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from arachnidae from mites
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/16—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from plants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966—Animal cells
    • G01N33/56977—HLA or MHC typing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0002—Fungal antigens, e.g. Trichophyton, Aspergillus, Candida
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Hematology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Toxicology (AREA)
  • Insects & Arthropods (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Botany (AREA)
  • Rheumatology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)

Abstract

Настоящее изобретение относится к композициям, содержащим пептиды, используемые для профилактики или лечения аллергии на клещей домашней пыли, а в частности к оптимальным комбинациям пептидов, используемых для профилактики или лечения указанной аллергии.
EA201070271A 2007-08-15 2008-08-15 Пептидная композиция для формирования толерантности к клещам домашней пыли и ее применение EA023303B1 (ru)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB0715949A GB0715949D0 (en) 2007-08-15 2007-08-15 Peptide with improved solubility
GB0716224A GB0716224D0 (en) 2007-08-20 2007-08-20 Peptides for vaccine
GB0723337A GB0723337D0 (en) 2007-11-28 2007-11-28 Peptide with reduced dimer formation
PCT/GB2008/002780 WO2009022156A2 (en) 2007-08-15 2008-08-15 Peptides for desensibilization against allergens

Publications (2)

Publication Number Publication Date
EA201070271A1 true EA201070271A1 (ru) 2010-12-30
EA023303B1 EA023303B1 (ru) 2016-05-31

Family

ID=40134075

Family Applications (2)

Application Number Title Priority Date Filing Date
EA201070271A EA023303B1 (ru) 2007-08-15 2008-08-15 Пептидная композиция для формирования толерантности к клещам домашней пыли и ее применение
EA201070270A EA018110B1 (ru) 2007-08-15 2008-08-15 Пептиды с пониженным уровнем образования димеров

Family Applications After (1)

Application Number Title Priority Date Filing Date
EA201070270A EA018110B1 (ru) 2007-08-15 2008-08-15 Пептиды с пониженным уровнем образования димеров

Country Status (24)

Country Link
US (7) US8652485B2 (ru)
EP (4) EP2083856B1 (ru)
JP (3) JP5697447B2 (ru)
KR (1) KR101699554B1 (ru)
CN (2) CN103272227B (ru)
AT (1) ATE482721T1 (ru)
AU (1) AU2008288283B2 (ru)
BR (1) BRPI0815395A2 (ru)
CA (1) CA2696563A1 (ru)
CY (2) CY1110981T1 (ru)
DE (1) DE602008002810D1 (ru)
DK (2) DK2083856T3 (ru)
EA (2) EA023303B1 (ru)
ES (1) ES2402956T3 (ru)
HK (2) HK1132194A1 (ru)
HR (2) HRP20100662T1 (ru)
IL (1) IL203943A (ru)
MX (1) MX2010001779A (ru)
NZ (2) NZ583361A (ru)
PL (1) PL2083856T3 (ru)
PT (2) PT2397154E (ru)
SI (2) SI2190473T1 (ru)
WO (4) WO2009022155A2 (ru)
ZA (2) ZA201001054B (ru)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0710529D0 (en) 2007-06-01 2007-07-11 Circassia Ltd Vaccine
CA2696563A1 (en) * 2007-08-15 2009-02-19 Circassia Limited Peptides for vaccine
DK2153841T4 (en) 2008-08-15 2016-02-15 Circassia Ltd Vaccine comprising Amb a 1 peptides for use in the treatment of ambrosieallergi
WO2010018384A1 (en) * 2008-08-15 2010-02-18 Circassia Limited T-cell antigen peptide from allergen for stimulation of il-10 production
GB0821806D0 (en) 2008-11-28 2009-01-07 Circassia Ltd Compositions with reduced dimer formation
CN103784952B (zh) 2009-02-05 2016-08-17 切尔卡西亚有限公司 用于疫苗的草肽
JP5860402B2 (ja) * 2009-10-08 2016-02-16 イオン メディックス インコーポレイテッド 室内空気由来細胞外ベシクルを含む組成物及びその用途
EP3170510A1 (de) * 2010-01-14 2017-05-24 Merck Patent GmbH Varianten der gruppe 5-allergene der süssgräser mit reduzierter allergenität durch mutagenese von prolinresten
GB201002559D0 (en) * 2010-02-15 2010-03-31 Circassia Ltd Birch peptides for vaccine
EP2575832B1 (en) * 2010-06-03 2017-07-26 ALK-Abelló A/S Pharmaceutical product comprising mite allergen extract(s) and a method for the manufacture thereof
US20130259884A1 (en) * 2010-09-24 2013-10-03 Alergenetica Sl Peptides
EP2460824A1 (en) * 2010-12-01 2012-06-06 Biomay Ag Hypoallergenic polypeptides for the treatment of house dust mite allergy
US9289476B2 (en) 2011-04-29 2016-03-22 Selecta Biosciences, Inc. Tolerogenic synthetic nanocarriers for allergy therapy
CA2838888A1 (en) * 2011-06-15 2012-12-20 Biotech Tools S.A. A method for the production of hydrolyzed allergens
KR20140050698A (ko) 2011-07-29 2014-04-29 셀렉타 바이오사이언시즈, 인크. 체액성 및 세포독성 t 림프구(ctl) 면역 반응을 발생시키는 합성 나노운반체
GB201208293D0 (en) * 2012-05-11 2012-06-20 Circassia Ltd Hydrochlorice salt of peptide
GB201209868D0 (en) * 2012-06-01 2012-07-18 Circassia Ltd Alternaria peptides
GB201209862D0 (en) 2012-06-01 2012-07-18 Circassia Ltd Cladosporium peptides
CA2889784C (en) 2012-10-30 2024-04-30 Monash University Novel immunotherapeutic molecules and uses thereof
JP7028556B2 (ja) 2013-05-03 2022-03-02 セレクタ バイオサイエンシーズ インコーポレーテッド 特定の薬力学的有効期間および免疫寛容の誘発のための抗原を有する免疫抑制剤の送達
EP3003365A1 (en) * 2013-06-05 2016-04-13 Maria R. Diaz-Torres T cell epitopes derived from alt a 1 or alt a 5 for the treatment of alternaria alternata allergy
ES2828448T3 (es) * 2013-06-06 2021-05-26 Anergis S A Péptidos superpuestos contiguos para el tratamiento de la alergia a los ácaros del polvo doméstico
AU2014328483B2 (en) 2013-09-25 2019-11-14 Aravax Pty Ltd Novel immunotherapeutic composition and uses thereof
MX2016008305A (es) * 2013-12-23 2017-01-11 Alk-Abelló As Combinaciones de peptidos y usos de los mismos en tratar alergia al acaro del polvo.
EA034692B1 (ru) 2014-03-31 2020-03-06 Бёрингер Ингельхайм Ветмедика Гмбх Улучшенные транспортные молекулы модулярного антигена и их применение
US10071114B2 (en) 2014-09-07 2018-09-11 Selecta Biosciences, Inc. Methods and compositions for attenuating gene expression modulating anti-viral transfer vector immune responses
US11452774B2 (en) 2015-02-20 2022-09-27 The Board Of Trustees Of The Leland Stanford Junior University Mixed allergen compositions and methods for using the same
US10143742B2 (en) 2015-02-20 2018-12-04 The Board Of Trustees Of The Leland Stanford Junior University Mixed allergen compositions and methods for using the same
US10149904B2 (en) 2015-02-20 2018-12-11 The Board Of Trusteees Of The Leland Stanford Junior University Mixed allergen compositions and methods for using the same
US10166286B2 (en) 2015-02-20 2019-01-01 The Board Of Trustees Of The Leland Stanford Junior University Mixed allergen compositions and methods for using the same
KR20170126001A (ko) * 2015-03-30 2017-11-15 고꾸리쯔 다이가꾸 호우징 오사까 다이가꾸 면역용 펩티드, 면역용 펩티드의 제조 방법, 그것을 포함하는 면역 질환용 의약 조성물, 및 면역 질환의 치료 방법
EP3355917A1 (en) 2015-09-30 2018-08-08 Boehringer Ingelheim Vetmedica GmbH Improved modular antigen transportation molecules and uses therof in animals
KR101858840B1 (ko) 2016-01-15 2018-05-16 단국대학교 천안캠퍼스 산학협력단 집먼지진드기 유래 알레르겐에 의한 과민반응 면역조절제
US11426451B2 (en) 2017-03-11 2022-08-30 Selecta Biosciences, Inc. Methods and compositions related to combined treatment with antiinflammatories and synthetic nanocarriers comprising an immunosuppressant
CN111465328A (zh) 2017-07-18 2020-07-28 前品牌股份有限公司 制备混合型变应原组合物的方法
WO2019055931A1 (en) * 2017-09-18 2019-03-21 Sutro Biopharma, Inc. ALPHA ANTI-FOLATE ANTIBODY-RECEPTOR CONJUGATES AND USES THEREOF
CN108078891B (zh) * 2017-12-28 2021-05-07 昆明赛诺制药股份有限公司 一种含美洲大蠊精提物的保湿修复洗面奶
CN107970199B (zh) * 2018-01-03 2021-05-07 昆明赛诺制药股份有限公司 一种含美洲大蠊精提物的牙膏
WO2020154476A1 (en) 2019-01-23 2020-07-30 Before Brands, Inc. Methods for making mixed allergen compositions
CN117362453B (zh) * 2023-12-08 2024-02-27 山东硕景生物科技有限公司 一种Derf1重组抗原、其制备方法及应用

Family Cites Families (82)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3174456D1 (en) 1980-07-18 1986-05-28 Du Pont Monothioglycerol as thiol-protector in lyophilized materials
US4442212A (en) * 1980-11-10 1984-04-10 E. I. Du Pont De Nemours & Company Monothioglycerol as thiol-protector in lyophilized materials
US5126399A (en) 1986-04-30 1992-06-30 Board Of Regents, The University Of Texas System Methods and compositions for the preparation and use of site-directed immunologic reagents
US4906564A (en) 1987-03-13 1990-03-06 The United States Of America As Represented By The Secretary Of The Army Antigenic determinants recognized by antibodies obtained using a pathogenic agent or a derivative thereof that presents a restricted set of antigens
EP0765936A1 (en) * 1987-06-17 1997-04-02 Institute For Child Health Research Cloning of mite allergens
FI891226A (fi) 1988-04-28 1989-10-29 Univ Leland Stanford Junior Reseptordeterminanter i anti-t-celler foer behandling av autoimmunsjukdom.
GB8812214D0 (en) 1988-05-24 1988-06-29 Hoffmann La Roche Use of peptide from circumsporozoite protein of p falciparum as universally recognized t-cell epitope
ES2013359A6 (es) 1988-11-04 1990-05-01 Corporacion Biolog Farmaceutic Procedimiento para la fabricacion de alergenos inmunogenicos polimerizados.
CA1340977C (en) 1988-11-15 2000-04-25 Monty Krieger Scavenger receptor protein and antibody thereto
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
US5399346A (en) 1989-06-14 1995-03-21 The United States Of America As Represented By The Department Of Health And Human Services Gene therapy
US6019972A (en) * 1989-11-03 2000-02-01 Immulogic Pharmaceutical Corporation Peptides of human T cell reactive feline protein (TRFP)
CA2073045C (en) 1989-11-03 2007-05-22 Malcolm L. Gefter A human t cell reactive feline protein (trfp) isolated from house dust and uses therefor
US5547669A (en) 1989-11-03 1996-08-20 Immulogic Pharma Corp Recombinant peptides comprising T cell epitopes of the cat allergen, Fel d I
US5433948A (en) * 1990-02-13 1995-07-18 Thomas; Wayne R. Cloning and sequencing of allergens of dermatophagoides (house dust mite)
AU655599B2 (en) 1990-09-11 1995-01-05 Institute For Child Health Research Cloning and sequencing of allergens of dermatophagoides (house dust mite)
US5593698A (en) 1990-10-31 1997-01-14 Autoimmune, Inc. Suppression of proliferative response and induction of tolerance with polymorphic class II MHC allopeptides
JP2632603B2 (ja) 1991-03-12 1997-07-23 アサヒビール株式会社 ヒト抗ＤｅｒｆＩＩＩｇＥ抗体が結合するペプチド
US6982326B1 (en) * 1991-07-12 2006-01-03 Immulogic Pharmaceutical Corporation Allergenic proteins and peptides from Japanese cedar pollen
US6555116B1 (en) 1991-10-12 2003-04-29 Regents Of The University Of California Alleviation of the allergenic potential of airborne and contact allergens by thioredoxin
EP0623168B1 (en) * 1991-10-16 2009-09-30 Merck Patent GmbH T cell epitopes of the major allergens from dermatophagoides (house dust mite)
US7288256B1 (en) * 1991-10-16 2007-10-30 Merck Patent Gmbh T cell epitopes of the major allergens from dermatophagoides (house dust mite)
WO1994024281A1 (en) 1993-04-14 1994-10-27 Immulogic Pharmaceutical Corporation T cell epitopes of the major allergens from dermatophagoides (house dust mite)
US6696061B1 (en) * 1992-08-11 2004-02-24 President And Fellows Of Harvard College Immunomodulatory peptides
US5460977A (en) 1992-08-14 1995-10-24 Torii & Co. Peptide having allergenicity
EP1277764A3 (en) * 1992-12-31 2003-01-29 Immulogic Pharmaceutical Corporation Allergenic proteins and peptides from dog dander and uses therefor
US5697103A (en) 1993-01-11 1997-12-16 Personal Expression I, Inc. Therapeutic glove
WO1994021675A2 (en) 1993-03-12 1994-09-29 Immulogic Pharmaceutical Corporation T cell epitopes of ryegrass pollen allergen
US6849427B1 (en) * 1993-03-12 2005-02-01 Immulogic Pharmaceutical Corp. Nucleic acids encoding a house dust mite allergen, Der p VII, and uses therefor
KR960701995A (ko) * 1993-04-14 1996-03-28 스테이시 엘. 채닝 더마토파고이드즈(집 먼지 진드기)로부터의 주요 알레르겐의 t세포 에피토프(t.cells epitopes of the major allergens from dermatophagoids(house dust mite))
EP0705108A4 (en) 1993-06-02 1997-08-06 Tvw Telethon Inst Child Health USE OF CRYPTIC PEPTIDES FOR INDUCTION IMMUNOLOGICAL TOLERANCE
WO1995006728A2 (en) 1993-08-13 1995-03-09 Immulogic Pharmaceutical Corporation T cell epitopes of ryegrass pollen allergen
US6180771B1 (en) * 1993-12-08 2001-01-30 Immulogic Pharmaceutical Corp. Nucleic acids encoding a house dust mite allergen, Der p III, and uses therefor
JPH07215996A (ja) 1994-01-31 1995-08-15 Torii Yakuhin Kk ダニアレルゲンのｂ細胞エピトープ
JPH09512014A (ja) * 1994-04-14 1997-12-02 イミユロジク・フアーマシユーチカル・コーポレーシヨン ダニアレルギー治療用の医薬ペプチド組成物
US5820862A (en) * 1994-04-14 1998-10-13 Immulogic Pharmaceutical Corporation T cell epitopes of the major allergens from dermatophagoides (house dust mite)
US6759234B1 (en) * 1994-09-02 2004-07-06 Immulogic Pharmaceutical Corporation Compositions and methods for administering to humans, peptides capable of down regulating an antigen specific immune response
IL115744A (en) 1994-10-27 2000-07-16 Akzo Nobel Nv Peptides comprising a subsequence of human cartilage glycoprotein - 39
DE19508192A1 (de) * 1995-03-09 1996-09-12 Behringwerke Ag Stabile Transglutaminasepräparate und Verfahren zu ihrer Herstellung
DE19545662C2 (de) * 1995-12-07 1998-11-26 Mannesmann Sachs Ag Selbstpumpendes hydropneumatisches Federbein mit innerer Niveauregulierung
EP0888541B1 (en) 1996-03-21 2005-05-25 Circassia Limited Cryptic peptides and method for their identification
CA2316015A1 (en) 1997-12-22 1999-07-01 Human Genome Sciences, Inc. Keratinocyte growth factor-2 formulations
WO1999034826A1 (en) 1998-01-09 1999-07-15 Circassia Limited Methods and compositions for desensitisation
FR2806727A1 (fr) * 2000-03-23 2001-09-28 Pf Medicament Molecule d'interet pharmaceutique comprotant en son extremite n-terminale un acide glutamique ou une glutamine sous forme de sel d'addition d'acide fort physiologiquement acceptable
KR20030062321A (ko) 2000-08-21 2003-07-23 아피토프 테크놀러지 (브리스톨) 리미티드 펩티드 선별 방법
WO2002017956A2 (en) * 2000-08-31 2002-03-07 Chiron Corporation Stabilized fgf formulations containing reducing agents
EP1373510B1 (en) * 2000-11-16 2008-11-19 Alk-Abello A/S Mutant allergens
US7786257B2 (en) * 2000-12-18 2010-08-31 University Of Kansas Signal-1/signal-2 bifunctional peptide inhibitors
US7264810B2 (en) 2001-01-19 2007-09-04 Cytos Biotechnology Ag Molecular antigen array
FR2820425B1 (fr) 2001-02-08 2004-01-02 Commissariat Energie Atomique Melange de peptides issus d'une proteine nef et leurs applications
JP4812951B2 (ja) 2001-03-21 2011-11-09 一般財団法人化学及血清療法研究所 特異性不明のｔ細胞のクローン化法及びその認識ペプチドリガンドの同定方法
GB0108752D0 (en) 2001-04-06 2001-05-30 Isis Innovation Peptide epitopes and uses thereof
US20040202654A1 (en) 2001-04-09 2004-10-14 Mayo Foundation For Medical Education & Research Methods and materials for cancer treatment
AUPR775401A0 (en) 2001-09-18 2001-10-11 Monash University Novel Epitopes and Uses Thereof
DK1450847T3 (da) 2001-11-13 2010-12-13 Genentech Inc Apo2-ligand/TRAIL-formuleringer og anvendelser deraf
JP4874522B2 (ja) * 2001-12-05 2012-02-15 サーカッシア リミテッド 免疫療法および系
AUPS148202A0 (en) 2002-04-02 2002-05-09 Monash University Immunotherapeutic and immunoprophylactic reagents
FR2841906B1 (fr) 2002-07-05 2006-08-18 Stallergenes Sa Molecule d'acide nucleique codant une preproproteine d'allergene d'un acarien du genre dermatophagoides ou euroglyphus et son utilisation pour la production dudit allergene dans les plantes
BR0312935A (pt) 2002-07-17 2005-06-21 Cytos Biotechnology Ag Partìcula semelhante a vìrus, muteìna, vetores para produzir a referida partìcula e proteìna recombinante, composição, processo para produção de fileira ordena e repetitva de antìgeno, molécula de ácido nucléico, célula hospedeira, método para produção da referida partìcula e uso da composição de vacina
US20040071718A1 (en) 2002-09-18 2004-04-15 Jaw-Ji Tsai Local nasal immunotherapy for allergen-induced airway inflammation
AU2004216925B2 (en) 2003-03-07 2010-04-22 London Health Sciences Centre Research Inc. Peptides associated with HLA-DR MHC class II molecules involved in autoimmune diseases
ATE368687T1 (de) 2003-06-26 2007-08-15 Merck Patent Gmbh Thrombopoietinproteine mit verbesserten eigenschaften
GB0315754D0 (en) * 2003-07-04 2003-08-13 Univ Aberdeen Pharmaceutical compositions
US20050053615A1 (en) * 2003-07-16 2005-03-10 Best Elaine A. Variants of mite group 1 allergens for the treatment of house dust mite allergy
AU2004288854B2 (en) 2003-11-10 2009-10-01 Arriva-Pharmaceuticals, Inc. Dry recombinant human alpha 1-antitrypsin formulation
WO2005103082A2 (en) 2004-04-23 2005-11-03 Novozymes A/S Group 1 mite polypeptide variants
WO2005121166A1 (en) 2004-06-10 2005-12-22 Monash University Novel immunointeractive molecules and uses thereof
US20060029551A1 (en) 2004-08-05 2006-02-09 Kui Liu Stable particle formulations of erythropoietin receptor agonists
US7732426B2 (en) * 2004-09-27 2010-06-08 Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo Isocyclomaltooligosaccharide (S) , isocyclomaltooligosaccharide-forming enzyme, their preparation and uses
EP1843779A2 (en) 2005-02-01 2007-10-17 Attenuon, LLC Compositions containing the anti-angiogenic phscn-peptide
FR2881746B1 (fr) 2005-02-07 2007-04-13 Centre Nat Rech Scient Epitopes t cd4+des antigenes de latence de type i et ii du virus epstein-barr aptes a etre reconnus par la majorite des individus de la population caucasienne et leurs applications
AU2006291835B2 (en) 2005-09-15 2012-04-05 Alk-Abello A/S A method for quantification of allergens
EP1829895A1 (en) 2006-03-03 2007-09-05 f-star Biotechnologische Forschungs- und Entwicklungsges.m.b.H. Bispecific molecule binding TLR9 and CD32 and comprising a T cell epitope for treatment of allergies
GB0609121D0 (en) 2006-05-09 2006-06-21 Univ Birmingham Peptide Therapy
AT503690A1 (de) 2006-06-09 2007-12-15 Biomay Ag Hypoallergene moleküle
PL2059256T3 (pl) * 2006-08-11 2017-02-28 Life Sciences Research Partners Vzw Immunogenne peptydy i ich zastosowanie w zaburzeniach immunologicznych
EP1958645A1 (en) 2007-02-13 2008-08-20 Biomay AG Peptides derived from the major allergen of ragweed (Ambrosia artemisiifolia) and uses thereof
US8148105B2 (en) 2007-03-16 2012-04-03 The Board Of Trustees Of The Leland Stanford Junior University Scaleable manufacturing process for cysteine endoprotease B, isoform 2
GB0710529D0 (en) * 2007-06-01 2007-07-11 Circassia Ltd Vaccine
CA2696563A1 (en) 2007-08-15 2009-02-19 Circassia Limited Peptides for vaccine
WO2009067191A2 (en) * 2007-11-16 2009-05-28 The General Hospital Corporation Methods and compositions for the treatment of hepatitis c virus (hcv) infection
GB2455108A (en) 2007-11-28 2009-06-03 Circassia Ltd T-Cell dependent method for detecting non-allergic or intrinsic disorders

Also Published As

Publication number Publication date
PL2083856T3 (pl) 2011-04-29
CN101820907B (zh) 2013-05-01
CY1110981T1 (el) 2015-06-11
EP2397154B1 (en) 2015-07-15
BRPI0815395A2 (pt) 2015-02-10
IL203943A (en) 2013-05-30
JP6040207B2 (ja) 2016-12-07
NZ583361A (en) 2012-10-26
US8652485B2 (en) 2014-02-18
HRP20100662T1 (hr) 2011-01-31
ATE482721T1 (de) 2010-10-15
DK2083856T3 (da) 2011-01-24
HK1164700A1 (en) 2012-09-28
CN101820907A (zh) 2010-09-01
JP2010536333A (ja) 2010-12-02
US20160289281A1 (en) 2016-10-06
JP5697447B2 (ja) 2015-04-08
PT2397154E (pt) 2015-10-29
EA023303B1 (ru) 2016-05-31
US9744222B2 (en) 2017-08-29
PT2083856E (pt) 2010-12-23
US20100298239A1 (en) 2010-11-25
WO2009022155A3 (en) 2009-06-04
KR20100068252A (ko) 2010-06-22
AU2008288283B2 (en) 2013-01-31
US9340580B2 (en) 2016-05-17
EP2083856B1 (en) 2010-09-29
ZA201001054B (en) 2011-04-28
CN103272227A (zh) 2013-09-04
SI2190473T1 (sl) 2013-05-31
WO2009022156A2 (en) 2009-02-19
WO2009022154A2 (en) 2009-02-19
KR101699554B1 (ko) 2017-01-25
ZA201001056B (en) 2011-04-28
ES2402956T3 (es) 2013-05-10
US20130336999A1 (en) 2013-12-19
NZ583362A (en) 2012-06-29
US20170157226A1 (en) 2017-06-08
US20140186403A1 (en) 2014-07-03
EA018110B1 (ru) 2013-05-30
CY1116828T1 (el) 2017-03-15
EP2190473B1 (en) 2013-01-16
US20110123558A1 (en) 2011-05-26
WO2009022156A3 (en) 2009-04-30
DE602008002810D1 (de) 2010-11-11
WO2009022155A2 (en) 2009-02-19
WO2009022157A2 (en) 2009-02-19
AU2008288283A1 (en) 2009-02-19
EP2286833A2 (en) 2011-02-23
US8551493B2 (en) 2013-10-08
HRP20130270T1 (hr) 2013-04-30
EP2286833A3 (en) 2011-09-14
HK1132194A1 (en) 2010-02-19
MX2010001779A (es) 2010-07-06
DK2190473T3 (da) 2013-03-25
EP2397154A2 (en) 2011-12-21
SI2083856T1 (sl) 2011-02-28
CA2696563A1 (en) 2009-02-19
JP2017061455A (ja) 2017-03-30
EP2190473A2 (en) 2010-06-02
CN103272227B (zh) 2014-12-10
EP2083856A2 (en) 2009-08-05
WO2009022154A3 (en) 2009-06-04
WO2009022157A3 (en) 2009-06-04
EA201070270A1 (ru) 2010-08-30
US20100260805A1 (en) 2010-10-14
JP2015057393A (ja) 2015-03-26
EP2397154A3 (en) 2012-04-04

Similar Documents

Publication Publication Date Title
EA201070271A1 (ru) Пептиды для получения вакцины
DE602008002693D1 (de) Vakzine-peptid-kombinationen gegen katzenallergie
EA201000844A1 (ru) Связывающие wise агенты и эпитопы
EA201001491A1 (ru) Репликационно-дефектные вакцины и вакцинные векторы против флавивирусов
MA33803B1 (fr) Inhibiteur de bromodomaine de benzodiazépine
BR112012014082A2 (pt) composições e métodos que compreendem variantes de protease
EA201000777A1 (ru) Ингибиторы репликации вируса иммунодефицита человека
MX2012007098A (es) Derivados fenolicos y su uso farmaceutico o cosmetico.
EA201200550A1 (ru) Фармацевтические композиции, включающие bi-1356 и метформин
UA94221C2 (en) Lipocalin protein
MX2012007161A (es) Derivados fenolicos y su uso farmaceutico o cosmetico.
EA200701825A1 (ru) Вакцины против хламидиоза
MA33208B1 (fr) Anticorps anti-fgfr3 et procédés d'utilisation de ceux-ci
EA201000950A1 (ru) Азолилметилоксираны, их применение, а также содержащие их средства
EA201171001A1 (ru) Пептиды трав для вакцины
EA201070219A1 (ru) Полимерные мультиэпитопные вакцины против гриппа
EA201270313A1 (ru) Композиции, которые индуцируют хелперное действие т-клеток
BRPI1015043A2 (pt) derivados de diazahomoadamantano e métodos de uso dos mesmos
UA108636C2 (xx) Пептид
EA201290792A1 (ru) Пептиды для вакцины против аллергии на березу
MY157782A (en) Compositions and methods for the treatment of xerostomia
MY155410A (en) Compositions and devices
MA32321B1 (fr) Pregn-4-en-21, 17 carbolactones substitués sur le noyau c, et préparations pharmaceutiques contenant ces derniers
EA201171414A1 (ru) Ингибиторы белков семейства iap
MX2009007929A (es) Uso de un primer alergeno del grupo 2 de acaro de polvo de casa para tratar alergia a un segundo alergeno del grupo 2 de acaro de polvo de casa.

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG MD TJ TM

MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): RU